Schizophrenia Research
Volume 119, Issue 1 , Pages 41-46 , June 2010

An abnormal relation between basal prolactin levels and prolactin response to 12.5µg TRH i.v. in drug-naïve patients with first-episode schizophrenia

  • Johan Spoov

      Affiliations

    • Diacor Medical Centre, Keskuskatu 7 C, 00100 Helsinki, Finland
    • Corresponding Author InformationCorresponding author. Fredrikinkatu 16 A 21, 00120 Helsinki, Finland. Tel.: +358 400 939384.
    • ,
  • Per-Erik Bredbacka

      Affiliations

    • Päijät-Häme Central Hospital, Keskussairaalakatu 7, 15850 Lahti, Finland
    • ,
  • Ulf-Håkan Stenman

      Affiliations

    • Department of Clinical Chemistry, University of Helsinki, 00029 Helsinki, Finland

Received 21 November 2009 ,Revised 15 February 2010 ,Accepted 26 February 2010.

References 

  1. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry. 1982;39(7):784–788
  2. Andreasen NC, Arndt S, Swayze 2nd V, Cizadlo T, Flaum M, O'Leary D, et al. Thalamic abnormalities in schizophrenia visualized though magnetic resonance imagew averaging. Science. 1994;266(5183):294–298
  3. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Arch. Gen. Psychiatry. 1995;52(5):341–351
  4. Bilder RM, Mukhergee S, Rieder RO, Pandurangi AK. Symptomatic and neuropsychological components of defect state. Schizophr. Bull. 1985;11(3):409–419
  5. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology. 2001;156(2–3):234–258
  6. Brunelin J, d'Amato T, van Os J, Cochet A, Suaud-Chagny MF, Saoud M. Effects of acute metabolic stress on the dopaminergic and pituitary–adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr. Res. 2008;100(1–3):206–211
  7. Burrow GN, May PB, Spaulding SW, Donabedian RK. TRH and dopamine interactions affecting pituitary hormone secretion. J. Clin. Endocrinol. Metab. 1977;45(1):65–72
  8. Connell PH. In: Amphetamine psychosis. Maudsley Monograph. vol. 5:London: Chapman & Hall; 1958;
  9. DE Lèan A, Ferland L, Drouin J, Kelly PA, Labrie F. Modulation of pituitary thyrotropin releasing hormone receptor levels by estrogen and thyroid hormones. Endocrinology. 1977;100(6):1469–1504
  10. DeMaria JE, Livingstone JD, Freeman ME. Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons. Brain Res. 2000;879(1–2):139–147
  11. Enjalbert A, Moos S, Carbonell M, Priam M, Kordon C. Prolactin inhibiting activity of dopamine-free subcellular fractions from rat mediobasal hypothalamus. Neuroendocrinology. 1977;24(3–4):147–161
  12. Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S, et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J. Clin. Pharmacol. 2004;44(10):1173–1184
  13. Hill-Samli M, McLeod RM. Interaction of thyrothropin-releasing hormone and dopamine on the release of prolactin from the rat anterior pituitary in vitro. Endocrinology. 1974;95(4):1189–1192
  14. Hinkle PM, Tashjian AH. Thyrotropin-releasing hormone regulates the number of its own receptors in the GH3 strain of pituitary cells in culture. Biochemistry. 1975;14(17):3845–3851
  15. Jacobs LS, Snyder PJ, Utiger RD, Daughaday WH. Prolactin response to thyrotropin-releasing hormone in normal subjects. J. Clin. Endocrinol. Metab. 1973;36(6):1069–1073
  16. Keks NA, Copolov DL, Singh BS. Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am. J. Psychiatry. 1987;144(10):1335–1337
  17. Kineman RD, Gettys TW, Frawley LS. Role of guanine nucleotide-binding proteins, Gi alpha 3 and Gs alpha, in dopamine and thyrotropin-releasing hormone signal transduction: evidence for competition and commonality. J Endocrinol. 1996;148(3):447–455
  18. Lieberman JA, Jody D, Alvir J, Ashtari M, Levy DL, Bogerts B, et al. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia: prevalence and clinical correlates. Arch. Gen. Psychiatry. 1993;50(5):357–368
  19. Mongioi A, Aliffi A, Vicari E, Coniglione F, Scapagnini U, D'Agata R. Down-regulation of prolactin secretion in men during continuous thyrotropin-releasing hormone infusion: Evidence for induction of pituitary desensitization by continuous TRH administration. J. Clin. Endocrinol. Metab. 1983;56(5):904–907
  20. Nerozzi D, Magnani A, Dastoli C, Ferri E, Capesciotti G, Antonozzi I, et al. Prolactin responses to domperidone in chronic schizophrenia. Psychiatry Res. 1992;42(2):159–169
  21. Noel GL, Suh HK, Frantz AG. L-dopa suppression of TRH-stimulated prolactin release in man. J. Clin. Endocrinol. Metab. 1973;36(6):1255–1258
  22. Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, et al. Regional dopamine synthesis in patients with schizophrenia using L-(beta-11C) DOPA PET. Schizophr. Res. 2009;108(1–3):78–84
  23. O'Donnell P, Grace A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophrenia Bull. 1998;24(2):267–283
  24. Peralta V, de Leon J, Cuesta J. Are there more than two syndromes in schizophrenia?. Brit. J. Psychiatry. 1992;161:335–343Sep
  25. Perret G, Valensi P, Hugues JN, Vassy R, Uzzan B. Use of pharamacokinetic model to characterize the thyrotropin (TSH) and prolactin (PRL) response to thyrotropin-releasing hormone (TRH) in man. Meth. and Find. Exptl. Clin. Pharmacol. 1988;10(6):387–391
  26. Post RM, Fink E, Carpenter WT, Goodwin FK. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch. Gen. Psychiatry. 1975;32(8):1063–1069
  27. Prange AJ, Loosen PT, Wilson IC, Meltzer HY. Behavioral and endocrine responses of schizophrenic patients to TRH (proliterin). Arch. Gen. Psychiatry. 1979;36(10):1086–1093
  28. Quijada M, Illner P, Krulich L, McCann SM. The effect of catecholamines on hormone release from anterior pituitaries and ventral hypothalami incubated in vitro. Neuroendocrinology. 1973;13(3):151–163
  29. Radnai B, Mravec B, Bodna'r I, Kubovcakova L, Fekete MI, Nagy GM, et al. Pivotal role of an endogenous tetrahydroisoquinoline, salsinol, in stress-and suckling-induced release of prolactin. Ann. N. Y. Acad. Sci. 2004;1018:183–191Jun
  30. Rieck RW, Ansari MS, Whetsell WO, Deutch AY, Kessler RM. Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology. 2004;29(2):362–372
  31. Schröder J, Buchsbaum MS, Siegel BV, Geider FJ, Niethammer R. Structural and functional correlates of subsyndromes in chronic schizophrenia. Psychopathology. 1995;28(1):38–45
  32. Shin SH, Papas S, Obonsawin MC. Current status of the rat prolactin releasing factor. Can. J. Physiol. Pharmacol. 1987;65(10):2036–20431987
  33. Silverstone T, Cookson J. Examining the dopamine hypothesis of schizophrenia and of mania using the prolactin response to antipsychotic drugs. Neuropharmacology. 1983;22(4):539–541
  34. Spoov J. Submaximal plasma prolactin response to TRH and dopamine activity in man. Pharmacopsychiatry. 1985;18(6):330–332
  35. Spoov J. Plasma prolactin response to submaximal stimulation by TRH and endogenous corticosteroids in man. Pharmacopsychiatry. 1987;20(3):96–98
  36. Spoov J, Karonen S-L. Urinary HVA reflects central dopamine activity in man. New Trends in Exp. Clin. Psychiat. 1987;3(2):93–99
  37. Spoov J, Bredbacka P-E, Appelberg B, Katila H, Karonen S-L, Rimon R, et al. Prolactin response to submaximal stimulation by TRH in nonaffective psychoses. Biol. Psychiatry. 1991;29(3):204–210
  38. Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol. Psychiatry. 1999;45(6):680–686

PII: S0920-9964(10)01169-2

doi: 10.1016/j.schres.2010.02.1074

Schizophrenia Research
Volume 119, Issue 1 , Pages 41-46 , June 2010

Article Tools

* Image Usage & Resolution